Mizuho analysts are betting the stock of the small biotech Terns Pharmaceuticals Inc. could rally sharply if the company’s oral weight-loss drug proves successful when data from an early-stage trial is released later this year.
Mizuho still recommends Terns Pharma as a cheap entry to the weight-loss-drug craze
